Multidisciplinary Guidelines for the Rational Use of Topical Non-Steroidal Anti-Inflammatory Drugs for Musculoskeletal Pain (2022) Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • (1) Background: Topical non-steroidal anti-inflammatory drugs (NSAIDs) are one of the primary drugs for treating musculoskeletal pain. However, there are currently no evidence-based recommendations about drug selection, drug administration, drug interactions, and use in special populations or other pharmacology-related content of such medications. To this end, the Chinese Pharmaceutical Association Hospital Pharmacy Professional Committee developed multidisciplinary guidelines on using topical NSAIDs to treat musculoskeletal pain. (2) Methods: The guidelines development process followed the World Health Organization guideline development handbook, the GRADE methodology, and the statement of Reporting Items for Practice Guidelines in Healthcare. The guideline panel used the Delphi method to identify six clinical questions to be addressed in the guidelines. An independent systematic review team conducted a systematic search and integration of evidence. (3) Results: Based on the balance between the benefits and harms of an intervention, the quality of the evidence, patient preferences and values, and resource utilization, the guideline panel developed 11 recommendations and nine expert consensuses on using topical NSAIDs to treat acute and chronic musculoskeletal pain. (4) Conclusions: Based on the effectiveness and overall safety of topical NSAIDs, we recommend patients with musculoskeletal pain use topical NSAIDs and suggest high-risk patients use topical NSAIDs, such as those with other diseases or receiving other concurrent treatments. The evidenced-based guidelines on topical NSAIDs for musculoskeletal pain incorporated a pharmacist perspective. The guidelines have the potential to facilitate the rational use of topical NSAIDs. The guideline panel will monitor the relevant evidence and update the recommendations accordingly.

authors

  • Shi, Chen
  • Ye, Zhaoming
  • Shao, Zengwu
  • Fan, Bifa
  • Huang, Cibo
  • Zhang, Yuan
  • Kuang, Xinying
  • Miao, Liyan
  • Wu, Xin’an
  • Zhao, Rongsheng
  • Chen, Xiao
  • Zhang, Bikui
  • Tong, Rongsheng
  • Hu, Xin
  • Fu, Zhijian
  • Lin, Jianhao
  • Li, Xiaomei
  • Sun, Tiezheng
  • Liu, Guoqiang
  • Dai, Haibin
  • Guo, Cheng
  • Zhang, Bo
  • Xu, Ting
  • Wen, Aidong
  • Zuo, Xiaocong
  • Liu, Jinmei
  • Chen, Xu
  • Li, Huibo
  • Wang, Jing
  • Luo, Min
  • Fan, Tingting
  • Qian, Yulan
  • Li, Xiu’mao
  • Qiu, Wenjie
  • Lin, Xiaowen
  • Pang, Yingchang
  • Hou, Yunfei
  • Yao, Difei
  • Kou, Wen
  • Sun, Bao
  • Hu, Can
  • Xia, Yanzhe
  • Zhao, Ming
  • Zhu, Changyu
  • Li, Qian
  • Zhang, Yu

publication date

  • February 15, 2023